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1. Introduction 
1.1 Motivation 
Cardiovascular diseases and coronary artery disease (CAD) represent the leading 
cause of death worldwide, even though, since 1968, the mortality rate has fallen 
(Mozaffarian, Benjamin et al. 2016). Atherosclerosis is the developmental process of 
atheromatous plaques and predominant pathology in coronary artery disease. 
Endothelial cell dysfunction is regarded as the classic stimulus for the development 
of atherosclerotic lesions. Also, the inflammatory process plays a significant role in 
the etiology of atherosclerosis. Circulating microparticles (MP) are released in 
abundance in patients with cardiovascular diseases and contribute to the initiation 
and development of atherosclerosis and its complications (accumulating in 
atherosclerotic lesions). Circulating microparticles play a role in the pathogenesis of 
atherosclerosis and could be a biomarker for the early diagnosis of coronary artery 
disease (Koganti, Eleftheriou et al. 2016). 
Endothelial-derived microparticles (EMP) are released into the circulatory system 
from activated or apoptosis endothelial cells and could influence cardiovascular 
disease pathogenesis via autocrine/paracrine signaling. EMP represent novel 
biological markers of endothelium dysfunction or injury as well as vasomotion 
disorders that are involved in the pathogenesis of cardiovascular, metabolic, and 
inflammatory diseases.  
The heterogeneous nuclear ribonucleoproteins (hnRNPs) bind to a specific region of, 
and actively regulate, target protein translation (Kim, Lee et al. 2017). HnRNPs 
specifically bind miRNAs through the recognition of specific motifs and control 
miRNAs loading into extracellular vesicles (Villarroya-Beltri, Gutierrez-Vazquez et al. 
2013). However, the exact function of hnRNP U and its related miRNAs are unknown. 
With this in mind, this study focuses on the role of the protein hnRNP U and its 
specific binding of miRNAs in human coronary artery endothelial cells (HCAEC). 
1.2 Coronary Artery Disease, Endothelial Cells, and Atherosclerosis 
The most important function of the endothelium is to prevent blood cell adhesion and 
inhibit clot formation. With extensive endothelial cell damage, injury, and apoptosis 
(due to classical cardiovascular risk factors, such as hypertension and smoking), the 
endothelium loses its integrity. In this sense, endothelium permeability increases and 
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inflammatory cells migrate from the blood vessel. Endothelial function is decisively 
influenced by the degree of endothelial cell apoptosis or death, such as endothelial 
denudation and plaque rupture, which result in acute coronary syndromes (ACS) 
(Lusis 2000). 
Endothelial cells (EC) also play a crucial role in atherosclerosis progression and its 
clinical manifestations in the coronary artery (Lusis 2000). At the cellular level, 
endothelial dysfunction and progressive atherosclerosis are based on a gradual loss 
of endothelial cells (Werner and Nickenig 2006). Experimental and clinical studies 
show that endothelial dysfunction is closely related to the determinants of 
atherosclerosis (Libby 2001) and could predict adverse events in CAD patients 
(Schachinger, Britten et al. 2000, Heitzer, Schlinzig et al. 2001); in addition, it can be 
quantitatively assessed by the measurement of MP plasma levels (Werner, 
Wassmann et al. 2006, Bulut, Maier et al. 2008). The relationship between MP with 
CAD and atherosclerosis will be introduced in section 1.3. 
1.3 The definition, history, and function of EMP 
Microparticles (MP, also known as microvesicles or circulating microvesicles) are 
fragments of plasma membrane ranging from 100 nm to 1000 nm that are shed from 
various cell types following apoptosis or activation. Wolf described microparticles in 
1967 (Wolf 1967) and, at that time, they were thought of as a kind of cellular debris. 
Over the last 50 years, however, numerous studies have demonstrated how 
circulating MP play a role in intercellular communication and transport mRNA, 
miRNA, and proteins between cells (Ratajczak, Miekus et al. 2006, McCarthy, 
Wilkinson et al. 2016). Circulating MP originate directly from the plasma membrane 
of the cell and reflect the antigenic content of the cells from which they arise. Thus, 
through flow cytometry, they can be classified and measured, for example, as 
endothelial microparticles (EMP), monocyte/macrophage microparticles (MMP), and 
platelet microparticles (PMP). MP contain cytoplasm and surface markers of their 
maternal cells of origin, such as CD31, CD144, and CD146 for endothelial cells, 
CD42 and CD61 for platelets, and CD45 for monocyte/macrophage cells (Hugel, 
Martinez et al. 2005, Prokopi, Pula et al. 2009). EMP are released into the circulation 
from activated and/or apoptosis endothelial cells and reflect disease severity and 
vascular and endothelial dysfunction (Distler, Pisetsky et al. 2005, Mause and Weber 
2010, Sierko, Sokol et al. 2015, McCarthy, Wilkinson et al. 2016). Under 
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physiological conditions, the concentration of EMP in the blood is clinically 
insignificant (Sierko, Sokol et al. 2015). Endothelial microparticles (EMP) have been 
developed as a promising new method of assessing endothelial injury. Circulating 
levels of EMP are thought to reflect a balance between cell stimulation, proliferation, 
apoptosis, and cell death (Berezin, Zulli et al. 2015). Plasma EMP levels increase in 
patients with cardiovascular diseases (VanWijk, VanBavel et al. 2003, Boulanger 
2010, Shantsila, Kamphuisen et al. 2010, Helbing, Olivier et al. 2014, Berezin, Zulli 
et al. 2015, Koganti, Eleftheriou et al. 2016); specific cardiovascular medications also 
affect plasma EMP levels (Amabile, Rautou et al. 2010). EMP are also biomarkers 
for the early detection of cardiovascular disease and its progression (Werner and 
Nickenig 2006, Sinning, Losch et al. 2011, Koganti, Eleftheriou et al. 2016, McCarthy, 
Wilkinson et al. 2016). Another function of EMP is to remove misfolded proteins, 
cytotoxic agents, and metabolic waste from the cell.  
In summary, EMP have diverse functions in cardiovascular disease and could 
represent novel biomarkers in cardiovascular risk assessment.  
1.4 MicroRNA: definition, discovery, biogenesis, and function 
MicroRNAs are tiny (21-24 nucleotides, about 22 nucleotides) non-coding RNA 
molecules found in plants, animals, and some viruses that regulate gene expression 
predominantly at the post-transcriptional level (Economou, Oikonomou et al. 2015). 
Most miRNAs are located within the cell, while some miRNAs, known as circulating 
miRNA or extracellular miRNA, have been found in the extracellular environment, 
including various biological fluids and cell culture media (Sohel 2016). 
A recent study indicates that miRNAs are involved in many different biological 
processes as well as innovative diagnostics and therapeutic approaches for 
diseases such as atherosclerosis and coronary artery disease (especially in 
myocardial infarction) (Economou, Oikonomou et al. 2015). MiRNAs have been 
found not only in cardiac tissue but also in circulating blood. Thus, miRNAs are 
involved in intercellular communication and have been shown to circulate in the 
bloodstream in stable forms (Economou, Oikonomou et al. 2015). Pioneering studies 
describe how down-regulated miRNAs or elevated miRNAs in plasma could be a 
diagnostic biomarker for patients with coronary artery disease (Fichtlscherer, De 
Rosa et al. 2010, Wang, Zhu et al. 2010). A few analyses have revealed that 
miRNAs play an essential role during heart development (Zhao, Ransom et al. 2007, 
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Chen, Murchison et al. 2008). More specifically, miRNA expression profiling studies 
have demonstrated that expression levels of specific miRNAs change in diseased 
human hearts, pointing to their involvement in cardiomyopathies (van Rooij, 
Sutherland et al. 2006, Tatsuguchi, Seok et al. 2007, Thum, Galuppo et al. 2007). 
Animal experiments have shown that particular miRNAs play a central role not only 
in heart development, but also in several pathological conditions, such as 
cardiogenesis, hypertrophic growth response, and cardiac conductance (Zhao, 
Samal et al. 2005, Care, Catalucci et al. 2007, Yang, Lin et al. 2007, Zhao, Ransom 
et al. 2007, Wagschal, Najafi-Shoushtari et al. 2015). 
The RNA-induced silencing complex (RISC) is a multiprotein complex, specifically a 
ribonucleoprotein, which could incorporate miRNA (Filipowicz, Bhattacharyya et al. 
2008). The mature 22 nucleotide miRNA products are incorporated into RISC. The 
mature miRNA bind RISC complex and regulate mRNA silencing in some ways, 
such as mRNA translation repression, mRNA degradation, heterochromatin 
formation, and DNA elimination. 
1.5 The RBP: definition, biogenesis, and function 
In circulating blood, there are abundant RNases, which rapidly degrade circulating 
RNAs in plasma. Why plasma miRNAs are relatively stable is unknown. Non-coding 
RNAs which include miRNAs almost always function as ribonucleoprotein complexes 
and not as naked RNAs (Matera, Terns et al. 2007). Evidence shows that miRNAs 
bind RNA binding proteins (RBPs) in the circulation or are protected by incorporation 
in MP (Connerty, Ahadi et al. 2015). Further, high-throughput sequencing data 
demonstrates that miRNA expressions are significantly different in MP and their 
parental cells, and thus miRNAs seem to be selectively packaged from cells into MP 
(Diehl, Fricke et al. 2012). 
RNA binding proteins are kinds of distinct cytoplasmic and nuclear proteins which 
contain a modular structure composed of RNA binding domains or motifs. These 
binding domains or motifs could bind the double or single stranded RNA which 
includes mRNA and non-coding RNA in cells. The RNA binding domain is composed 
of 80 amino acids and could bind to a short single stranded RNA sequence. 
Numerous binding motifs or domains have been found, such as RNA recognition 
motif, dsRNA binding domain, and zinc finger (Lunde, Moore et al. 2007). 
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RNA binding proteins have an important role in the post-transcriptional control of 
RNAs, such as through splicing, polyadenylation, mRNA stabilization, and mRNA 
localization and translation. Although RBPs play a crucial role in the post-
transcriptional regulation of gene expression and cellular function, relatively few 
RBPs have been studied systematically (Glisovic, Bachorik et al. 2008, Hogan, 
Riordan et al. 2008). Most RBPs exist as complexes of protein and pre-mRNA in the 
nucleus and quickly export mature RNA from the nucleus to the cytoplasm. These 
kinds of RBPs are also called heterogeneous ribonucleoprotein particles (hnRNPs) 
and will be discussed in section 1.6. 
1.6 The hnRNPs family and hnRNP U: definition, biogenesis, and function. 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are multi complexes of RNA 
and protein present in the cell nucleus and cytoplasm. Their most important function 
is to bind the 3′- and 5′-UTRs of mature mRNAs, transport them from the nucleus to 
the cytoplasm, and promote protein synthesis (Geuens, Bouhy et al. 2016). 
Moreover, they play important roles in multiple aspects of nucleic acid metabolism, 
such as the packaging of nascent transcripts, mRNA stabilization, alternative splicing, 
and translational regulation.  
The hnRNP family have different molecular weights ranging from 34 to 120 kDa, and 
they have been named alphabetically from A to U. All the above genes belong to the 
subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins and 
their name and binding domain or motif, as shown in Table 1. 
The hnRNPs are not only related to influence pre-mRNA processing and other 
aspects of mRNA metabolism and transport but are also related to non-coding RNA, 
such as microRNA. Recently, several results have shown that hnRNPs bind several 
microRNAs in cell or exosomes. HnRNP A1 binds miR-18a in vivo (Guil and Caceres 
2007). HnRNPA2B1 specifically binds miRNA-198 and miRNA-601 in exosomes in 
vivo (Villarroya-Beltri, Gutierrez-Vazquez et al. 2013). HnRNP K binds miR-122 with 
a nanomolar dissociation constant in vitro (Santangelo, Giurato et al. 2016). HnRNP 
Q directly binds miR-3470a, miR-194-2-3p, miR-6981-5p, miR-690, miR-365-2-5p, 
and miR-29b-3p in exosomes in vitro (Fan, Sutandy et al. 2015). Also, Laura 
Santangelo illustrated how hnRNPA2B1 binds miR-3470a, miR-194-2-3p, miR-365-
2-5p, miR-6981-5p, miR-690, and miR-125b-5p in vitro (Fan, Sutandy et al. 2015). 
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Further, Konishi’s results revealed that hnRNP A1 binds miR-26a, 29a, 29b, 107, 
584, and 1229* (Konishi, Fujiya et al. 2015). 
 
 
Name  RNA Binding domain or motif 
HnRNP A (A0, A1, A1L1, A1L2, A3) RRM, RGG, Glycine rich 
hnRNP AB (AB, A2B1) RRM, RGG, Glycine rich 
hnRNP B1 RRM, RGG, Glycine rich 
hnRNP C (C, CL) RRM, Acidic rich 
hnRNP D (D, DL) KH  
hnRNP F qRRM, Glycine rich 
hnRNP G RRM, Glycine rich 
hnRNP H (H1, H2, H3) qRRM, Glycine rich 
hnRNP K KH, Proline-rich, others 
hnRNP I RRM 
hnRNP L (L, LL) RRM, Glycine rich 
hnRNP M RRM 
hnRNP P RRM, RGG, Glycine rich 
hnRNP Q RRM, Acidic rich 
hnRNP R RRM, RGG, Acidic rich, others 
hnRNP U (U, UL1, UL2, UL3) RGG, Acidic rich, others 
Table 1: The name and structure of the hnRNPs family. 
HnRNPs - heterogeneous nuclear ribonucleoproteins: RRM, RNA recognition motif; RGG, 
RNA-binding domain consisting of Arg-Gly-Gly repeats; qRRM, quasi-RNA recognition motif; 
KH, K-homology domain. 
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Figure 1 sets out a schematic diagram showing the way in which hnRNPs 
specifically sort miRNAs into EMP and secretion. 
 
 
Figure 1: Schematic diagram showing how hnRNPs specifically sort miRNAs into EMP and 
secretion. 
Modified from Santangelo, L., et al., The RNA Binding Protein SYNCRIP Is a Component of 
the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting. Cell Rep, 2016. 17(3): p. 
799–808. 
 
HnRNP U (also known as scaffold attachment factor SAF-A, AFA, HNRPU, SAF-A, 
U21.1, hnRNP U, HNRNPU-AS1) is one of the most abundant hnRNPs in the heart 
and belongs to the family of hnRNPs. The hnRNP U protein has the highest 
molecular weight in the hnRNP family. The hnRNP U protein has two conserved 
binding domains that could bind DNAs and RNAs (Hegde, Banerjee et al. 2012). The 
N-terminal domain of hnRNP U mediates its binding to DNA and the C-terminal with 
the arginine-glycine-glycine motif is responsible for its RNA binding activities (Kim 
and Nikodem 1999). HnRNP U has several roles in mRNA metabolism, including the 
packaging of nascent mRNAs, alternative splicing, and regulation of translation (Han, 
Tang et al. 2010). The hnRNP U protein is an important regulator of cellular 
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processes, such as mRNA stability and de-stabilization, mRNA transport, mRNA 
transcription, and protein translation (Han, Tang et al. 2010). The hnRNP U protein 
plays an essential role in the development and function of mice’s hearts (Ye, Beetz 
et al. 2015). HnRNP U-deficient hearts also cause cardiomyocyte disarray, leading to 
sudden death in mice (Ye, Beetz et al. 2015). Recent data shows that hnRNP U 
interacts with all classes of regulatory non-coding RNAs in the nucleus, including all 
small nucleolar RNAs (snRNAs) (Xiao, Tang et al. 2012). 
The alleged role of hnRNP U in HCAEC has, according to present knowledge, not 
yet been addressed. In this regard, the present study hypothesizes that hnRNP U 
could bind microRNA and influence cellular function in vitro. 
1.7 Aims 
In this study, we aim to explore the role of hnRNP U and its associated miRNA in 
HCAEC and endothelial cell-derived MP.  
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2. Materials and methods 
2.1 Cell culture and EMP generation 
Human coronary artery endothelial cells (HCAEC, Promo Cell, Heidelberg, Germany) 
were cultured in an EC growth medium with endothelial growth medium Supplement 
Mix (Promo Cell, Heidelberg, Germany) under standard cell culture conditions (37°C, 
5% CO2). Cells of passage 7~8 were used when 90% confluent. Endothelial 
microparticles were generated from HCAEC, as previously described, with minor 
changes (Jansen, Yang et al. 2013). Briefly, HCAEC were starved by subjecting to 
basal medium without growth medium supplements for 24 hours to induce apoptosis. 
After starvation, all supernatant medium was collected and centrifuged twice 
(1500 × g, 15 min and 20 000 × g, 40 min) at 4 degrees Celsius. The obtained EMP 
were washed in sterile PBS (pH 7.4) and pelleted again at 20 000 × g. 
Microparticles derived from si-hnRNP U and scrambled siRNA-treated HCAEC were 
defined as EMPsi-hnRNP U and EMPsiRNA negative control. By generating EMPsi-hnRNP U and 
EMPsiRNA negative control derived from HCAEC transfected si-hnRNP U and scrambled 
siRNA, 80% confluent HCAEC were stimulated with 20 mM si-hnRNP U and 
scrambled-siRNA for 48 hours (Federici, Menghini et al. 2002) and then subjected to 
a basal medium without growth medium supplements for 24 hours in order to 
generate EMP. Isolated EMP were re-suspended in sterile PBS and used fresh.  
2.2 Western blot  
HCAEC were lysed in a RIPA buffer (Sigma, cat#0278, USA) with protease inhibitor 
cocktail tablets (Roche, cat#1071140, Germany) on ice for 30 minutes. Then lysates 
were ultrasonicated 3 times for 15 seconds and centrifuged at 13000 rpm for 15 min. 
After this, a Lowry protein assay (Bio-Rad, Munich, Germany) was performed to 
measure protein concentration. Equal amounts of protein (15-20 μg) and SDS-
loading buffer were mixed and boiled, run into an 8% SDS electrophoresis buffer, 
and transferred onto polyvinylidene difluoride (PVDF) membranes. Membranes were 
then blocked in a 5% BSA-PBS for one hour at room temperature. Next, blot 
membranes were incubated overnight at 4 degrees Celsius with the appropriate 
primary antibodies, such as anti-hnRNP U (Abcam Biotechnology, ab10297), hnRNP 
K (Abcam Biotechnology, ab39975), hnRNP A2B1(Abcam Biotechnology, ab6102), 
and anti-GAPDH (Hytest,cat#:5G4Mab6c5). The membranes were washed three 
times with a 0.1% PSB-T and then incubated with HRP-conjugated secondary 
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antibodies (goat anti-mouse peroxidase, Thermo Scientific, cat#31446) for one hour 
at room temperature. Proteins were revealed by chemiluminescence using the 
ECLTM primer western blotting detection kit (GE Healthcare, cat#2232, UK). GAPDH 
was the loading control. Image J software was used to analyze the grayscale. 
2.3 EMP mass spectrometry 
Proteins were in-gel digested using a previously described protocol (Bonzon-
Kulichenko, Perez-Hernandez et al. 2011). Briefly, EMP were isolated and lysis by 
RIPA buffer was performed and then loaded into a SDS-PAGE gel. A protein band 
was stained with Coomassie brilliant blue and digested with trypsin. Ammonium 
bicarbonate extracted the resulting tryptic peptides. Peptide identification was 
performed in cooperation with the Institute of Biochemistry and Molecular Biology, 
University of Bonn. The MS/MS raw files were searched according to the Human 
Swiss-Prot database (http://www.uniprot.org/uniprot UniProt release, 20168 
sequence entries for human). SEQUEST results were confirmed using the probability 
ratio method (Martinez-Bartolome, Navarro et al. 2008), and false discovery rates 
were calculated using the refined method (Navarro and Vazquez 2009). Peptide and 
scan-counting were performed assuming as positive events those with an FDR equal 
to or lower than 5%. 
2.4 RNA immunoprecipitation (RIP)  
Each 10 cm dish of endothelial cells was lysed in 1ml of RIPA buffer and incubated 
for pre-clearing with pre-washed Protein G/A Dynabeads (Roche, 
REF#11719416001/11719408001, Germany) (40 μl per 10 cm plate cells) (1 h, 4°C). 
A total of 40 μl of Dynabeads were washed twice and re-suspended in 200 μl 
containing 10 μg mouse anti-hnRNP U (Abcam, ab10297), or mouse anti-IgG control 
(Abcam, ab200699), and then they were incubated for one hour at room temperature. 
Mouse Ig G was used as an isotype control. Lysates were incubated with antibody-
conjugated Dynabeads (1.5 h, 4°C). Antibody-target protein conjugated Dynabeads 
complex was washed three times with an RIPA buffer. After this, the pellets were an 
hnRNP U- anti hnRNP U antibody-Dynabeads complex, and this was divided equally 
and transferred to clean tubes. 
For protein detection, an SDS-loading buffer was mixed and boiled at 95°C for 
10 min and processed for western blot, according to section 2.2.  
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For microarray and RT-PCR analysis, 500 μl of Trizol lysis reagent (Ambion Life 
technology, REF15596018) was added and samples were vortexed. Then, the total 
RNA was isolated from the hnRNP U- anti hnRNP U antibody-Dynabeads complex 
by Trizol extraction method, according to sections 2.5 and 2.6.  
2.5 Taqman microRNA array 
RNA isolated from HCAEChnRNP U-IP and HCAECIg G-IP was converted to cDNA by 
priming with a mixture of looped primers (Human MegaPlex Primer Pools; Applied 
Biosystems). The miRNA profiles were performed with TaqMan® Array MicroRNA 
Cards for a total of 384 different assays specific to human miRNAs under standard 
real-time PCR conditions. Quantitative real-time PCR was conducted by Applied 
Biosystems 7900HT thermocycler using the manufacturer’s recommended program 
Detailed analysis of the results was performed with DataAnalysis v3.0 Software 
(Applied Biosystems). All CT values above 40 were defined as undetectable. More 
than a four-fold difference was considered indicating a significant change. 
2.6 The expression of mRNA and miRNA 
Human coronary artery endothelial cells and EMP were lysed in Trizol (Ambion Life 
technology, REF15596018). Total RNA was extracted according to the 
manufacturer’s instructions and quantified using a NanoDrop spectrophotometer.  
For mRNA expression, 1 μg (HCAEC) or 200ng (EMP) of the extracted total RNA 
was reversely transcribed to cDNA. An Omniscript@RT Kit (Qiagen, Germany) was 
used according to the manufacturer’s protocols. The single-stranded cDNA was 
amplified by a real-time polymerase chain reaction with the TaqMan system (ABI-
7500 (Life Technologies, Germany) Fast PCR System). All primers were bought from 
Life Technologies (hnRNP U, Hs00244919, Life Technologies, Germany; GAPDH, 
Hs03929097, Life Technologies, Germany). GAPDH was used as an endogenous 
control. The delta Ct method was used to quantify relative mRNA expression. 
For miRNA expression, 10 ng of total RNA was reversely transcribed to cDNA. 
TaqMan®microRNA Reverse Transcription kit (Applied Biosystems, Life 
Technologies, Germany) was used according to the manufacturer’s protocols. Then, 
quantitative real-time PCR was performed and Taqman miRNA assays (Applied 
Biosystems) were used to measure miRNA-30c, miRNA-100, and miRNA-24 levels 
on a 7500 HT Real-Time PCR machine (Applied Biosystems). All primers were 
bought from Life Technology (hsa-miR-30c-5p, Hs000419; hsa-miR-24, Hs000402; 
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hsa-miR-100, Hs000437). RNU-6b served as an endogenous control. MiRNA-30c 
and miRNA-24 mimics were used to create the standard curve and calculate the 
copy number. Copy numbers were used to quantify absolute miRNAs expression. 
2.7 Transfection in HCAEC 
To generate miRNA-30c-overexpressing and miRNA-30c-down-expressing HCAEC 
lines, HCAEC were transfected with microRNA-30c mimic, microRNA-30c inhibitor, 
and microRNA control (100pM, all from Applied Biosystems, miRNA-30c Cat # 
A25576) using Lipofectamine 2000 (Invitrogen, Life Technology, REF#1168-019) for 
24 hours. Functional assays were performed in 48 hours. 
To generate miRNA-24-overexpressing and miRNA-24-down-expressing HCAEC 
lines, HCAEC were transfected with microRNA-24 mimic, microRNA-24 inhibitor, and 
microRNA control (100pM, all from Applied Biosystems, miRNA-24 Cat. # A25576) 
using Lipofectamine 2000 (Invitrogen, Life Technology, REF#1168-019) for 24 hours. 
Functional assays were performed in 48 hours. 
2.8 The protein of hnRNP U silencing 
To generate hnRNP U down-expressing HCAEC lines, HCAEC were transfected with 
si-hnRNP U. Scrambled siRNA served as a negative control. HCAEC were 
transfected with si-hnRNP U (Ambion, cat#AM16708, ID 145414) and negative 
control siRNA (Ambion, cat#AM4611, ID 145414). HCAEC were transfected with a 
pool of single-stranded siRNAs targeting hnRNP U for 48 hours. Cells were 
incubated in a 10 cm dish and 6-well plate, separately adding 300pM and 100pM si-
hnRNP U and siRNA negative control. 
2.9 Flow cytometry analysis 
In order to count the number of EMP, TrucountTM tubes were used (BD Biosciences, 
cat#340334) and analyzed with FACS BD LSR II. Annexin V positive (AnnV+) with 
CD 31+ positive EMP were counted using Trucount beads. The formula for 
calculating for EMP concentrations was as follow:  
 
number of events for annexin V 
number of events in Trucount bead region
×
   number of Trucount beads per test 
test volume
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EMP was used at a concentration of 2000 AnnV+ EMP/µl for all experiments. Nile 
red particles sized from 0.7 to 0.9 µm (Spherotech, USA) were used as reference 
beads and set the gate for EMP. Briefly, 100 µl of EMP was re-suspended in PBS, 
adding 4 µl CD31+APC antibody (Invitrogen, Cat#A16224, USA) in each tube, and 
incubated for 45 minutes in a dark environment at room temperature. Next, 5 µl of 
Annexin V-FITC (BD Biosciences, Cat#556419, USA) was added to each tube. After 
incubation for 15 min in a dark environment at room temperature, PBS was washed 
twice and centrifuged for 20 minutes at 20 000 g. Pelleted EMP were re-suspended 
in a 200 µl annexin V-binding buffer (10mM HEPES, pH 7.4, 140mM NaCl, 2.5 mM 
CaCl2), and were measured by flow cytometry and analyzed with FACS BD LSR II. 
2.10 Boyden chamber assay  
HCAEC (passage 7) were seeded onto the upper compartment of Boyden chambers 
(BD Falcon, Germany) with Transwell polycarbonate inserts (8.0µm pore size) for 
one hour. EMP were added to the lower well of the Boyden chamber and given a soft 
shaking, then incubating for six hours to allow for cell migration. The insert was 
removed and the upper side of the insert was scraped off with a rubber cell lifter. 
Inserts were fixed with 4% fresh paraformaldehyde and stained with DAPI. Cell 
migration was quantified by counting the cells of five random microscopic fields 
(×100) in each well. 
2.11 Wound scratch assay  
Passage 7 HCAEC were used when grown to confluence in a 6-well plate, and a 
sterile pipette (100 ul) was used to make a scratch. After the scratch, EMP were 
added to the cells. Cells were photographed in a marked position at 0, 6, and 10 
hours. The remaining cell-free area was measured and correlated (in percentage) to 
the initially scratched area. 
2.12 Proliferation assay 
HCAEC in the basal medium were deprived of growth medium supplements and 
coincubated with EMP for six hours. The cells were then pulsed with BrdU (10µM, 
BD) for six hours. Cells were fixed and denatured. BrdU incorporation was detected 
using rat anti-BrdU (Abcam, ab53435) and secondary antibody anti-rat cy3 (Jackson 
ImmunoResearch, cat#709-165-149, USA). Nuclei were stained with DAPI (Vector 
Laboratories, CA94010, USA). All photographs were taken using a Zeiss Axiovert 
200M microscope and AxioVision software. 
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2.13  Statistical analysis 
All data is expressed as the Mean ± SD or Mean ± SEM. Means between two 
categories were compared using a two-tailed unpaired Student’s t-test. A one-way 
ANOVA test was applied for comparisons of categorical variables when the data 
fitted the homogeneity of variance. For post hoc analysis, a Bonferroni test was 
used. Statistical significance was assumed. All P-values less than 0.05 were 
considered a statistically significant difference. All statistical analyses were 
performed with GraphPad Prism 5. 
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3. Results 
3.1 hnRNPs were expressed in HCAEC  
Endothelial microparticles (EMP) regulate several processes in cardiovascular 
biology by transferring proteins or nucleic acids and can act as cell-to-cell 
messengers. To determine which proteins are expressed in EMP, mass 
spectrometry (MS) assay was done, and the RNA binding protein database 
(http://rbpdb.ccbr.utoronto.ca/) was used for further analysis. The MS results showed 
that there were nearly 2500 different kinds of proteins in EMP, out of which 125 were 
RNA binding proteins, as illustrated in Figure 3.1.1. Table 1 lists the twenty highest 
expressed RNA binding proteins in EMP; from this, hnRNP U, hnRNP K, and hnRNP 
A2B1 are the top three expressed RNA binding proteins. 
Also, the total HCAEC and EMP proteins were lysed and a western blot was 
performed. Unfortunately, hnRNP U, K, and A2B1 could not be found in EMP. 
However, hnRNP U showed higher expression than hnRNP K and hnRNP A2B1 in 
HCAEC, as illustrated in Figure 3.1.2 (in this sense, hnRNP U bands are stronger 
than hnRNP K and A2B1). Therefore, hnRNP U was focused upon as a target 
protein for further experiments. 
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Figure 2 3.1.1: EMP- Mass Spectrometry results. 
125 types of RNA binding proteins were predicted in EMP. 
 
Figure 3 3.1.2: The expression of hnRNPs in HCAEC. 
The proteins hnRNP U, K and A2B1 were confirmed by the western blot. The bands of 
hnRNP U were strongest in the three bands. Unluckily, three kinds of hnRNP could not be 
detected in EMP by the western blot.  
 
 - 24 - 
Accession Protein Area Description 
Q00839 HNRNPU 5,091E8 Heterogeneous nuclear ribonucleoprotein U OS 
=Homo sapiens GN=HNRNPU PE=1 SV=6 - 
[HNRPU_HUMAN] 
P22626 HNRNPA2B1 5,023E8 Heterogeneous nuclear ribonucleoproteins A2/B1 OS 
=Homo sapiens GN=HNRNPA2B1 PE=1 SV=2 - 
[ROA2_HUMAN] 
P61978 HNRPK 3,904E8 Heterogeneous nuclear ribonucleoprotein K OS 
=Homo sapiens GN=HNRNPK PE=1 SV=1 - 
[HNRPK_HUMAN] 
P07910 HNRPC 3,672E8 Heterogeneous nuclear ribonucleoproteins C1/C2 OS 
=Homo sapiens GN=HNRNPC PE=1 SV=4 - 
[HNRPC_HUMAN] 
Q14103 HNRPD 3,661E8 Heterogeneous nuclear ribonucleoprotein D0 OS 
=Homo sapiens GN=HNRNPD PE=1 SV=1 - 
[HNRPD_HUMAN] 
P04406 G3P 3,336E8 Glyceraldehyde-3-phosphate dehydrogenase OS 
=Homo sapiens GN=GAPDH PE=1 SV=3 - 
[G3P_HUMAN] 
P52272 HNRPM 3,101E8 Heterogeneous nuclear ribonucleoprotein M OS 
=Homo sapiens GN=HNRNPM PE=1 SV=3 - 
[HNRPM_HUMAN] 
Q15365 PCBP1 3,092E8 Poly(rC)-binding protein 1 OS=Homo sapiens GN 
=PCBP1 PE=1 SV=2 - [PCBP1_HUMAN] 
P31943 HNRH1 3,089E8 Heterogeneous nuclear ribonucleoprotein H OS 
=Homo sapiens GN=HNRNPH1 PE=1 SV=4 - 
[HNRH1_HUMAN] 
P23246 SFPQ 3,008E8 Splicing factor, proline- and glutamine-rich OS 
=Homo sapiens GN=SFPQ PE=1 SV=2 - 
[SFPQ_HUMAN] 
P55795 HNRH2 2,864E8 Heterogeneous nuclear ribonucleoprotein H2 OS 
=Homo sapiens GN=HNRNPH2 PE=1 SV=1 - 
[HNRH2_HUMAN] 
Q15366 PCBP2 2,851E8 Poly(rC)-binding protein 2 OS=Homo sapiens GN 
=PCBP2 PE=1 SV=1 - [PCBP2_HUMAN] 
P52597 HNRP 2,026E8 Heterogeneous nuclear ribonucleoprotein F OS 
=Homo sapiens GN=HNRNPF PE=1 SV=3 - 
[HNRPF_HUMAN] 
P09651 A1 2,002E8 Heterogeneous nuclear ribonucleoprotein A1 OS 
=Homo sapiens GN=HNRNPA1 PE=1 SV=5 - 
[ROA1_HUMAN] 
Q15233 NONO 1,980E8 Non-POU domain-containing octamer-binding protein 
OS 
=Homo sapiens GN=NONO PE=1 SV=4 - 
[NONO_HUMAN] 
P43243 MATR3 1,860E8 Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=2 
- [MATR3_HUMAN] 
P11940 PABP1 1,767E8 Polyadenylate-binding protein 1 OS 
=Homo sapiens GN=PABPC1 PE=1 SV=2 - 
[PABP1_HUMAN] 
P26599 PTBP1 1,441E8 Polypyrimidine tract-binding protein 1 OS 
=Homo sapiens GN=PTBP1 PE=1 SV=1 - 
[PTBP1_HUMAN] 
O14979 HNRDL 1,408E8 Heterogeneous nuclear ribonucleoprotein D-like OS 
=Homo sapiens GN=HNRPDL PE=1 SV=3 - 
[HNRDL_HUMAN] 
P51991 HNRNPA3 1,370E8 Heterogeneous nuclear ribonucleoprotein A3 OS 
=Homo sapiens GN=HNRNPA3 PE=1 SV=2 - 
[ROA3_HUMAN] 
 
Table 2: The twenty highest expressed RNA binding proteins in EMP.  
HnRNP U, hnRNP K, and hnRNP A2B1 were the top three expressed RNA binding proteins.  
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3.2 MiRNA-30c and miRNA-24 strongly bind to cellular hnRNP U 
According to the western blot results depicted in Figure 3.1.2, hnRNP U showed the 
highest expression of the three candidate proteins in HCAEC. Thus, we focused on 
the hnRNP U function in HCAEC.  
HnRNP U is an important regulator of cellular processes, such as mRNA transport, 
mRNA transcription, and protein translation (Han, Tang et al. 2010). As hnRPN U is 
an RNA-binding protein, the aim of this study is to assess whether miRNAs are 
bound to hnRNP U and might mediate its cellular processes and functions. 
To assess whether some miRNAs specifically bind to the hnRNP U protein, hnRNP 
U-RIP-microarray analysis from HCAEC was conducted. The immunoprecipitation of 
hnRNP U was performed in HCAEC and subsequent western blot analysis revealed 
a proper isolation of hnRNP U from the precipitant (Figure 3.2.1). Total RNA was 
eluted from isolated hnRNP U. Microarray analysis showed that miRNA-30c, miRNA-
100, and miRNA-24 were the miRNAs bound to hnRNP U with the highest 
expression compared to the control. RT-PCR analysis confirmed the higher 
expression of miRNA-30c and miRNA-24 in isolated hnRNP U compared to the 
control (Figure 3.2.2: 17.32- and 3.24- fold higher; p-values of 0.04 and 0.10 
respectively). However, the result for miR-100 showed no significant differences 
(Figure 3.2.2). Overall, the microarray and RT-PCR results revealed that hnRNP U 
binds miRNA-30c and miRNA-24. Therefore, the following experiments focused on 
the relationship between miRNA-30c and miRNA-24 with hnRNP U.
 
Figure 4 3.2.1: Immunoprecipitation-western blot result. 
Western blot analysis revealed a proper isolation of hnRNP U from the precipitant. Ig G 
antibody as control. 
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Figure 5 3.2.2: MicroRNAs expression in protein hnRNP U.  
The RT-PCR analysis confirmed the higher expression of miRNA-30c and miRNA-24 in 
isolated hnRNP U compared to the control. However, the result of miR-100 showed no 
significant differences. 
3.3 The expression of hnRNP U, miRNA-30c, and miRNA-24 in HCAEC and 
EMP 
To investigate the relationship between hnRNP U with miRNA-30c and miRNA-24, 
hnRNP U was down-regulated in HCAEC by si-RNA. The RT-PCR and western blot 
analyses confirmed the inhibitory efficacy of hnRNP U at the mRNA and protein 
levels. RT-PCR results revealed that the hnRNP U mRNA level decreased when 
hnRNP U-siRNA was transfected for 24 hours (Figure 3.3.1: siRNA-negative control 
vs. si-hnRNP U,1.00 ± 0.19 vs. 0.57 ± 0.12, n=8, p=0.07). The western blot results 
showed that hnRNP U-siRNA significantly decreased the protein levels of hnRNP U 
after being transfected with hnRNP U-siRNA for 48 hours (Figure 3.3.2: siRNA-
negative control vs. si-hnRNP U, 1±0 vs. 0.63±0.02, n=3, p=0.001). Furthermore, 
miRNA-30c and miRNA-24 both showed lower expression in the hnRNP U down-
regulation group than in the control group (Figure 3.3.3: miRNA-30c copy number, si-
hnRNP U vs. siRNA-negative control, 1.52 ± 0.33 vs. 0.75 ± 0.72 ×106, n=8, p=0.04; 
miRNA-24 copy number, si-hnRNP U vs. siRNA-negative control, 7.22 ± 0.70 vs. 
9.54 ± 0.75 ×106, n=8, p=0.046). 
As we know, EMP are released into the circulation from activated endothelial cells 
and reflect disease severity, including vascular and endothelial dysfunction, which 
could influence disease pathogenesis via autocrine/paracrine signaling. 
Subsequently, this study focused on whether the decrease in the hnRNP U protein 
could affect the EMP released and miRNA levels in EMP.  
EMP was isolated and total RNA was extracted. The RT-PCR result showed that the 
expression of miRNA-30c and miRNA-24 in EMPsi-hnRNP U, derived from si-hnRNP U 
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transfected HCAEC, were both expressed higher than the EMPsiRNA negative control, 
which were derived from si-RNA negative control transfected HCAEC (Figure 3.3.3: 
miRNA-30c copy number, EMPsi-hnRNP U vs. EMPsiRNA negative control, 3.15± 0.98 vs. 0.86 
± 0.24 ×104, n=6, p=0.04; Figure 3.3.4 miRNA-24 copy number, EMPsi-hnRNP U vs. 
EMPsiRNA negative control, 5.28± 1.58 vs. 11.50 ± 2.1 ×104, n=6, p=0.03).  
Furthermore, the flow cytometry result revealed that si-hnRNP U transfected HCAEC 
might have no influence on EMP secretion (Figure 3.3.5: EMP numbers per 
microliter, si-hnRNP U vs. siRNA-negative control, 5.4 ± 0.77 vs. 4.60 ± 0.38×103, 
n=5, p=0.37). 
In summary, the data showed that miRNA-30c and miRNA-24 levels decreased 
consistently with the hnRNP U mRNA and protein level downregulation. Thus, the 
association of miRNA-30c and miRNA-24 with hnRNP U was confirmed. However, 
with the decrease of hnRNP U, the level of miRNA-30c and miRNA-24 were both 
expressed higher in EMPsi-hnRNP U when compared with the EMPsiRNA negative control.  
 
 
 
Figure 6 3.3.1: The mRNA expression of hnRNP U in HCAEC. 
RT-PCR result revealed that the hnRNP U mRNA level decreased when transfected si-
hnRNP U 24 hours. n=11. 
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Figure 7 3.3.2: The protein of hnRNP U expression in HCAEC. 
The western blot result revealed the protein level of hnRNP U was significantly decreased 
when transfected si-hnRNP U 48 hours. n=3. 
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Figure 8 3.3.3: MiRNA-30c and miRNA-24 expression in HCAECsi-hnRNP U and the 
HCAECsiRNA negative control. 
RT-PCR result revealed that the copy number value of miRNA-30c and miRNA-24 were 
significantly decreased in HCAECsi-hnRNP U when compared with the HCAECsiRNA negative control. 
MiRNA-30c mimic and miRNA-24 mimic were used to make the standard curve and 
calculate the copy number. n=8 
 
Figure 9 3.3.4: MiRNA-30c and miRNA-24 expression in EMPsi-hnRNP U and EMPsiRNA negative 
control. 
RT-PCR result revealed that the copy number value of miRNA-30c and miRNA-24 were 
significantly increased in EMPsi-hnRNP U and the EMPsiRNA negative control. MiRNA-30c mimic and 
miRNA-24 mimic were used to make the standard curve and calculate the copy number. n=6.  
 
Figure 10 3.3.5: EMP concentration results.  
The flow cytometry result revealed that si-hnRNP U transfected HCAEC might have no 
influence on the EMP secretion. n=5. 
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3.4 MiRNA-30c and miRNA-24 expression in supernatant. 
To explore the underlying mechanisms of the controversial miRNA expression, such 
as in hnRNP U-negative HCAEC and EMP, the miRNA-30c and miRNA-24 
expression in the supernatant was measured.  
The results showed that in the HCAEC supernatant, miRNA-30c, and miRNA-24 
showed higher expression after hnRNP U downregulation when compared with the 
control group, whereas there was no difference in cells (Figure 3.4.2: miRNA-30c 
copy number, si-hnRNP U supernatant vs. siRNA-negative control supernatant, 
16.85 ± 2.26 vs. 4.52 ± 0.92×105, n=6, p<0.01; Figure 3.4.4: miRNA-24 copy number, 
si-hnRNP U supernatant vs. siRNA-negative control supernatant, 5.83 ± 1.08 vs. 
49.46± 8.33 ×105, n=6, p<0.01).  
The data confirms that si-hnRNP U HCAEC might secrete miRNA-30c and miRNA-
24 into the supernatant.  
 
 
Figure 11 3.4.2: MiRNA-30c expression in the supernatant.  
MiRNA-30c were expressed more highly in the si-hnRNP U cell supernatant than the siRNA-
negative control supernatant. n=6. Supernatant, HCAEC culture supernatant.  
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Figure 12 3.4.4: MiRNA-24 expression in the supernatant.  
MiRNA-24 were expressed more highly in the si-hnRNP U cell supernatant than the siRNA-
negative control supernatant. n=6. Supernatant, HCAEC culture supernatant.  
3.5 EMPsi-hnRNP U inhibits HCAEC migration and promotes HCAEC 
proliferation 
The protein hnRNP U could actively regulate the packaging of specific miRNA 
into extracellular vesicles, and also seems to regulate miRNA-30c and miRNA-24 
release into the cell supernatant, as shown in Figure 3.3.4. In this way, miRNA-
containing EMP represent cell-to-cell messengers and regulate the function of 
HCAEC. 
To observe the function of EMPsi-hnRNP U or the EMPsiRNA negative control on HCAEC, 
migration assay and proliferation assay were performed. Wound scratch assay 
results indicated that the EMPsi-hnRNP U group obviously inhibited while the EMPsiRNA 
negative control group promoted the migration abilities of HCAEC cells (Figure 3.5.1: 
EMPsi-hnRNP U vs. EMPsiRNA negative control, 6 and 10 hours, 40.73. ± 1.92 % vs. 55.49 ± 
3.21%, 60.68 ± 2.80% vs. 78.76 ± 3.86%, n=12, p<0.01 and p<0.01). Moreover, a 
transwell migration assay was applied to study the influence of EMPsi-hnRNP U and the 
EMPsiRNA negative control on the migration of HCAEC cells (Figure 3.5.2: EMPsi-hnRNP U vs. 
the EMPsiRNA negative control, 159.7 ± 8.46 vs. 216.3 ± 19.43, n=6, p=0.02). In line with 
the wound scratch assay results, the transwell migration revealed a promigratory 
effect of EMPsi-hnRNP U. The proliferation assay results indicated that the EMPsi-hnRNP U 
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group promoted HCAEC proliferation when compared with the EMPsiRNA negative control 
group (Figure 3.5.3: EMPhnRNP U-siRNA vs. EMPcrambled-siRNA, 9.99 ± 0. 31% vs. 8.92 ± 
0.35%, n=6, p=0.04).  
Taken together, EMPsi-hnRNP U inhibits HCAEC migration and promotes HCAEC 
proliferation.  
 
 
Figure 13 3.5.1: EMPsi-hnRNP U inhibits HCAEC migration (wound scratch assay). 
HCAEC were coincubated with EMPsi-hnRNP U or the EMPsiRNA negative control. The area of 
migration was shown at 0, 6, and 10 hours respectively. Data was shown as the mean ± SD. 
Culture medium: 20% complete medium with 80% basal medium. All experiments were 
repeated three times. n=12. 
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Figure 14 3.5.2: EMPsi-hnRNP U inhibits HCAEC migration (transwell migration assay). 
HCAEC were coincubated with EMPsi-hnRNP U or the EMPsiRNA negative control. Data was shown as 
the numbers of migrated cells. All experiments were repeated three times. n=6  
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Figure 15 3.5.3: EMPsi-hnRNP U promotes HCAEC proliferation. 
HCAEC in the completed medium were stimulated with EMPsi-hnRNP U or the EMPsiRNA negative 
control for 18 hours and then incubated with BrdU for 6 hours. Immunofluorescence assay was 
performed. BrdU and nuclei were stained with Cy3 (red) and DAPI (blue) respectively. BrdU 
staining cells were counted by Image J software and the percentage of BrdU-positive cells in 
total cells was calculated and analyzed. Magnification ×200, n=6. 
 
3.6 Overexpression of miRNA-30c inhibits HCAEC migration and promotes 
HCAEC proliferation 
To clarify the function of miRNA-30c in HCAEC, HCAEC with miRNA-30c 
mimic/control/inhibitor was transfected. The overexpression of miRNA-30c markedly 
improved proliferation and inhibited the migration of HACEC cells, whereas the 
inhibition of endogenous miRNA-30c significantly suppressed proliferation and 
promoted the migration of HCAEC when compared with the negative control. Wound 
scratch assay results indicated that the overexpression of miRNA-30c obviously 
inhibited HCAEC migration, while the downregulation of miRNA-30c promoted the 
migration abilities of HCAEC (Figure 3.6.1: mimic vs. control vs. inhibitor, 6 and 10 
hours, 41.29 ± 2.09% vs 44.18 ± 1.31% vs. 48.14 ± 1.41%, 57.20 ± 2.13% vs. 64.20 
± 2.06% vs. 66.70 ± 1.74%, n=12, p=0.02 and p=0.01). Moreover, a transwell 
migration assay was applied in order to study the influence of miRNA-30c on the 
migration of HCAEC cells (Figure 3.6.2: mimic vs. control vs. inhibitor, 133.3± 7.41 
vs. 151.3 ± 5.87 vs. 193.9 ± 5.15, n=6, p<0.01). In line with the wound scratch assay 
results, the transwell migration revealed a promigratory effect of miRNA-30c. The 
proliferation assay result indicated that overexpression of miRNA-30c obviously 
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promoted HCAEC proliferation, while downregulation of miRNA-30c inhibited the 
proliferation abilities of HCAEC (Figure 3.6.3: mimic vs. control. vs. inhibitor 15.72± 
0.42% vs. 12.71 ± 0.57% vs. 11.94 ± 0.60%, n=6, p<0.01).  
In this sense, the results showed that up-regulated miRNA-30c expression promotes 
HCAEC proliferation and inhibits HCAEC motility in vitro. 
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Figure 16 3.6.1: Overexpression of miRNA-30c inhibits endothelial cell migration (wound 
scratch assay). 
Confluent HCAEC in the basal medium were coincubated with miRNA-30c mimic, control or 
inhibitor. The area of migration was shown at 0, 6, and 10 hours respectively. Quantitative 
analysis of migration was measured as a percentage of the total cell-free area. Data was 
shown as the mean ± SD. Culture medium: 20% complete medium with 80% basal medium. 
All experiments were repeated three times. n=12. 
 
 
 
 
 
Figure 17 3.6.2: Overexpression of miRNA-30c inhibits endothelial cell migration (transwell 
migration assay). 
HCAEC were treated with miRNA-30c mimic, control or inhibitor. Data represent the 
numbers of migrated cells. All experiments were repeated three times. n=6. 
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Figure 18 3.6.3: Overexpression of miRNA-30c promotes endothelial cell proliferation. 
BrdU incorporation was determined by immunofluorescence (red). Nuclei were stained with 
DAPI (blue). The percentage of BrdU-positive cells was compared. Magnification, ×200. 
BrdU, indicates bromodeoxyuridine; DAPI, 4′,6-diamidino-2-phenylindole; and HCAEC, 
human coronary artery endothelial cell. n=6. 
3.7 Overexpression of miRNA-24 promotes HCAEC proliferation and inhibits 
HCAEC migration 
To clarify the function of miRNA-24 in HCAEC, HCAEC with miRNA-24 
mimic/control/inhibitor was transfected. The overexpression of miRNA-24c markedly 
promoted proliferation and inhibited the migration of HACEC, whereas the inhibition 
of endogenous miRNA-24 significantly suppressed proliferation and promoted the 
migration of HCAEC when compared with the negative control. Wound scratch assay 
results indicated that the overexpression of miRNA-24 was obviously inhibited, while 
the downregulation of miRNA-24 promoted the migration abilities of HCAEC cells 
(Figure 3.7.1: mimic vs. control vs. inhibitor, 6 and 10 hours, 34.08 ± 1.82 % vs. 
39.95 ± 2.37 % vs. 41.82 ± 1.66 %, 41.16 ± 2.62 % vs. 46.20 ± 2.00 % vs. 51.52 ± 
2.17%, p=0.02 and p=0.01). Moreover, a transwell migration assay was applied in 
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order to study the influence of miRNA-30c on the migration of HCAEC cells (Figure 
3.7.2: mimic vs. control vs. inhibitor, 137.8± 6.02 vs. 177.7 ± 12.59 vs. 189.1 ± 11.07, 
p=0.01). In line with the wound scratch assay results, transwell migration revealed a 
promigratory effect of miRNA-24. The proliferation assay results indicated that the 
overexpression of miRNA-30c was obviously promoted, while the downregulation of 
miRNA-30c inhibited the proliferation abilities of HCAEC (Figure 3.7.3: mimic vs. 
control vs. inhibitor 14.02± 0. 63 % vs. 12.36 ± 0.61 % vs. 11.01 ± 0.49 %, p<0.01).  
Taken together, it was found that miRNA-24 was likely to play a major role in cell 
migration, invasion, and proliferation. 
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Figure 19 3.7.1: Overexpression of miRNA-24 inhibits endothelial cell migration (wound 
scratch assay). 
Confluent HCAEC in the basal medium were coincubated with miRNA-24 mimic, control or 
inhibitor. The area of migration was shown at 0, 6, and 10 hours respectively. Quantitative 
analysis of migration was measured as a percentage of the total cell-free area. Data was 
shown as the mean ± SD. Culture medium: 20% complete medium with 80% basal medium. 
All experiments were repeated three times. n=12. 
 
 
 
 
 
Figure 20 3.7.2: Overexpression of miRNA-24 inhibits endothelial cell migration (transwell 
migration assay). 
HCAEC were treated with miRNA-24 mimic, control or inhibitor. Data represent the numbers 
of migrated cells. All experiment were repeated three times. n=6. 
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Figure 21 3.7.3: Overexpression of miRNA-24 promotes endothelial cell proliferation. 
BrdU incorporation was determined by immunofluorescence (red). Nuclei were stained with 
DAPI (blue). The percentage of BrdU-positive cells was compared. Magnification, ×200. 
BrdU, indicates bromodeoxyuridine; DAPI, 4′,6-diamidino-2-phenylindole; and HCAEC, 
human coronary artery endothelial cell. n=6. 
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4. Discussion  
This report has shown that the hnRNP U protein binds to miRNA-30c and miRNA-24 
in HCAEC cells in vitro. Furthermore, it has been demonstrated that the 
downregulation of hnRNP U in HCAEC also decreases the levels of both miRNA-30c 
and miRNA-24. No differences in EMP secretions between HCAEC transfected with 
either si-hnRNP U or the siRNA negative control were observed. miRNA-30c and 
miRNA-24 expression levels in HCAEC were higher in the cell culture supernatant 
when transfected with si-hnRNP U compared to a transfection with the siRNA 
negative control. EMP derived from HCAEC transfected with si-hnRNP U inhibit 
HCAEC migration and promote proliferation. Furthermore, upregulation of miRNA-
30c and miRNA-24 levels in HCAEC also inhibit HCAEC migration and promote 
proliferation.  
Recent studies have shown that hnRNP A1 (Guil and Caceres 2007, Konishi, Fujiya 
et al. 2015), hnRNP A2B1 (Villarroya-Beltri, Gutierrez-Vazquez et al. 2013, Fan, 
Sutandy et al. 2015), hnRNP Q (Santangelo, Giurato et al. 2016), and hnRNP K (Fan, 
Sutandy et al. 2015) could bind to several miRNAs in cells and exosomes. However, 
there has been no report exploring whether miRNAs are specifically binding to the 
hnRNP U protein. In this study, microarray and RT-PCR results confirmed that 
hnRNP U specifically binds to miRNA-30c and miRNA-24 in HCAEC in vitro (Figures 
3.2.2 and 3.2.3). Furthermore, the expression levels of miRNA-30c and miRNA-24 
were decreased with the downregulation of hnRNP U in HCAEC (Figures 3.3.3 and 
3.3.4). Together, this data demonstrates that hnRNP U specifically binds miRNA-30c 
and miRNA-24 in HCAEC in vitro. As shown in Figure 1.5.1, in the hnRNP U protein 
there are many binding domains, such as the acid-rich domain, the Gly-rich domain, 
the RGG box (consisting of Arg-Gly-Gly repeats), and other binding domains (Bi, 
Yang et al. 2013, Vu, Park et al. 2013, Geuens, Bouhy et al. 2016). The hnRNP U 
protein binds RNA through these binding domains and transfers RNA from nucleus 
to cytoplasm. In several reports, hnRNP U protein was demonstrated to specifically 
bind to the mRNAs or miRNAs (Vu, Park et al. 2013, Geuens, Bouhy et al. 2016). 
Unfortunately, the exact binding domain and sequence for the hnRNP U interaction 
with miRNA-30c and miRNA-24 is unknown. Further experiments in this direction 
need to be performed.  
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Because miRNAs in EMPs determine cellular biological effect, it was also decided to 
detect the miRNA-30c and miRNA-24 expression in EMP. The results indicated that 
both the miRNA-30c and miRNA-24 expression levels in EMP were higher in EMPs 
derived from HCAEC transfected with si-hnRNP U than in the siRNA negative control 
(Figures 3.3.3 and 3.3.4). However, both the miRNA-30c and miRNA-24 expression 
levels were lower in HCAEC transfected with si-hnRNP U than in the siRNA negative 
control. To clarify why the levels of miRNA-30c and miRNA-24 were inverted 
between EMP and HCAEC after transfection, the miRNA-30c and miRNA-24 levels 
in the cell culture medium were measured. The miRNA-30c and miRNA-24 were 
both expressed higher in the si-hnRNP U cell supernatant than in the siRNA 
negative control medium (Figures 3.4.1 and 3.4.2).  
RNA sequencing (RNA-seq) and microarray data have shown that miRNAs are 
differentially enriched in extracellular vesicles (EV) compared to their producer cells 
(Valadi, Ekstrom et al. 2007, Skog, Wurdinger et al. 2008, Gibbings, Ciaudo et al. 
2009, Simons and Raposo 2009, Guduric-Fuchs, O'Connor et al. 2012, Nolte-'t Hoen, 
Buermans et al. 2012, Villarroya-Beltri, Gutierrez-Vazquez et al. 2013, Vu, Park et al. 
2013). Interestingly, specific miRNAs are enriched in EVs in a cell type-dependent 
fashion. All of the above findings suggest that the sorting of specific miRNA species 
to extracellular vesicles may be actively regulated. However, the underlying 
mechanisms for how miRNAs are sorted into microparticles and the significance of 
miRNA transfer to acceptor cells remain largely unknown. Villarroya-Beltri et al. 
showed that sumoylated hnRNPA2B1 could be used to monitor the sorting of 
miRNAs into exosomes through binding to specific motifs (GGAG) (Villarroya-Beltri, 
Gutierrez-Vazquez et al. 2013). Thus, chaperone proteins might interact with specific 
motifs or sequences in certain miRNAs and guide the miRNA sorting into EVs 
(Villarroya-Beltri, Gutierrez-Vazquez et al. 2013). In addition, Squadrito et al. 
demonstrated that microRNA sorting into exosomes is modulated by the levels of 
endogenous natural targets (Vu, Park et al. 2013). Squadrito has also shown that not 
only miRNAs and their targeted transcripts promote bidirectional miRNA relocation 
from the cytoplasm to multivesicular bodies, but they also modulate miRNA sorting to 
exosomes (Squadrito, Baer et al. 2014).  
It has been demonstrated here that miRNA-30c and miRNA-24 were both expressed 
higher in the si-hnRNP U basal cell supernatant than in the siRNA negative control 
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supernatant. There was no difference in HCAEC expression levels of miRNA-30c 
and miRNA-24 between cells transfected with si-hnRNP U and those transfected 
with the siRNA negative control. However, the miRNA-30c and miRNA-24 
expression levels in the supernatant were expressed higher for the si-hnRNP U than 
for the siRNA negative control in the same cells (Figures 3.4.1 and 3.4.2). The 
machinery how microRNAs specifically secretion and packing into EMP remains to 
be determined in future endeavors.  
Flow cytometry results showed that there were no differences in the amounts of EMP 
secretions between the HCAEC transfected with si-hnRNP U vs. the siRNA negative 
control (Figure 3.4.3). Thus, the downregulation of hnRNP U did not influence the 
secretion of EMP. 
The next step in the project was to determine the role of EMP derived from HCAEC 
transfected with either si-hnRNP U or the siRNA negative control. The data showed 
that the EMPsi-hnRNP U inhibits HCAEC motility and promotes HCAEC proliferation 
(Figures 3.5.1-3). It also showed that up-regulated miRNA-30c and miRNA-24 in 
HCAEC inhibited HCAEC motility and proliferation (Figures 3.6.1-3 and Figures 
3.7.1-3). Thus, it can be speculated that the miRNA-30c and miRNA-24 in EMP 
might affect HCAEC motility and proliferation. Earlier studies have revealed that 
miRNA-30c (Zhou, Xu et al. 2012, Xia, Chen et al. 2013, Ling, Han et al. 2014, Wu, 
Zhang et al. 2015, Zhang, Yu et al. 2015) and miRNA-24 (Amelio, Lena et al. 2012, 
Fiedler, Stohr et al. 2014, Zhu, Shan et al. 2015, Li, Wang et al. 2016, Yang, Chen et 
al. 2016, Ehrlich, Hall et al. 2017) inhibit cell motility in vivo and in vitro. However, 
another study reported that miRNA-30c and miRNA-24 have inverse functionality in 
cell motility and proliferation, in that miRNA-30 (Liu, Li et al. 2016) and miRNA-24 
(Ma, She et al. 2014, Zhao, Hu et al. 2016, Yu, Jia et al. 2017) promote cell motility. 
Thus, miRNA-30c and miRNA-24 play different functions in different cell lines. This 
study’s data showed upregulation miRNA-30c and miRNA-24 inhibit HCAEC motility 
in vitro. 
Several studies have shown that miRNA-30c (Zhou, Xu et al. 2012, Ling, Han et al. 
2014, Zhong, Chen et al. 2014, Xing, Zheng et al. 2015) and miRNA-24 (Giglio, 
Cirombella et al. 2013, Xu, Liu et al. 2013, Ma, She et al. 2014, Lu, Wang et al. 2015, 
Zhao, Liu et al. 2015, Sun, Xiao et al. 2016, Zhao, Hu et al. 2016, Yu, Jia et al. 2017) 
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promote cell proliferation. Furthermore, other studies have reported that miRNA-30c 
(Tanic, Yanowsky et al. 2012, Dobson, Taipaleenmaki et al. 2014) and miRNA-24 
(Lal, Navarro et al. 2009, Amelio, Lena et al. 2012, Song, Yang et al. 2013, Fiedler, 
Stohr et al. 2014, Inoguchi, Seki et al. 2014, Zhang, Zhang et al. 2015, Zhu, Shan et 
al. 2015, Li, Wang et al. 2016, Yang, Chen et al. 2016, Ehrlich, Hall et al. 2017) 
inhibit cell proliferation in cells. Fiedler reported that miRNA-24 had no effect on cell 
cycle progression in HASMCs (Fiedler, Stohr et al. 2014) and Xia demonstrated that 
miRNA-30c also had no effect on proliferation in the A549 cell line (Xia, Chen et al. 
2013). The data in this study indicates that miRNA-30c and miRNA-24 promote 
HCAEC proliferation in vitro.  
Unfortunately, no research to date has focused on miRNA-30c and miRNA-24 in 
HCAEC’s motility and proliferation. In this study, it has been confirmed that miRNA-
30c and miRNA-24 could inhibit HCAEC migration and promote HCAEC proliferation. 
Although there were several discoveries during these studies, there are also many 
questions remaining as well as limitations regarding the work performed. First, 
hnRNP U has many motifs and binding domains which could interact with many 
different miRNAs. This experiment only focused on two types of miRNAs according 
to our RIP-microarray result. Therefore, other miRNAs which also bind to hnRNP U 
are sure to be missed. These miRNAs also have several key functions in HCAEC 
and EMP, and only a few of them have been explored. Second, Electrophoretic 
mobility shift assay (EMSA) is also critical in confirming miRNA binding to hnRNP U 
in vitro. EMSA is a common affinity electrophoresis technique used to study protein–
RNA interactions performed in vitro. This procedure can determine whether a protein 
is capable of binding to a given RNA sequence and can sometimes indicate if more 
than one protein molecule is involved in the binding complex. Third, experiments in 
the downregulation and upregulation of hnRNP U in HCAEC are both necessary in 
studying the function of hnRNP U in HCAEC, and the upregulation experiments have 
not yet been conducted. Fourth, in vivo animal experiments are also necessary. In 
the coming months, all of these experiments will be performed in order to confirm 
these preliminary results. 
In summary, it has been identified that the hnRNP U protein binds to miRNA-30c and 
miRNA-24 in vitro. EMP derived from HCAEC cells transfected with si-hnRNP U 
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negatively regulates HCAEC’s motility and positively promotes proliferation. 
This study has highlight that:  
1) hnRNP U binds to miRNA-30c and miRNA-24 in vitro. 
2) miRNA-30c and miRNA-24 levels decreased with the transfection of si-hnRNP U 
in HCAEC. 
3) miRNA-30c and miRNA-24 levels increased in EMPsi-hnRNP U and the cell culture 
medium.  
4) EMPsi-hnRNP U inhibits HCAEC’s migration and promotes HCAEC proliferation in 
vitro. 
5) Overexpression of miRNA-30c and miRNA-24 inhibits endothelial cell migration 
and promotes proliferation in vitro.  
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5. Abstract 
The protein heterogeneous nuclear ribonucleoprotein U (hnRNP U) plays an 
essential role in the development and function of the heart. The hnRNP U protein in 
human coronary artery endothelial cells (HCAEC) mediates its function by binding 
microRNAs (miRNAs). Endothelial microparticles (EMP) derived from HCAEC 
regulate several processes in cardiovascular biology by transferring miRNAs to 
target cells. In this study, we aimed to explore the function of hnRNP U in HCAEC 
and EMP.  
We found that the hnRNP U protein binds to microRNA-30c (miRNA-30c) and 
microRNA-24 (miRNA-24) in HCAEC in vitro. Furthermore, the downregulation of 
hnRNP U in HCAEC decreases the levels of both miRNA-30c and miRNA-24. 
Downregulation of hnRNP U did not affect the number of EMP released from 
HCAEC. The miRNA-30c and miRNA-24 expression levels were higher in both EMP 
and the supernatant when transfected with si-hnRNP U compared to transfection 
with the siRNA negative control. EMP derived from HCAEC transfected with si-
hnRNP U inhibit HCAEC migration and promote proliferation. Furthermore, 
upregulated miRNA-30c and miRNA-24 expression both inhibit HCAEC motility and 
promote proliferation in vitro. 
HnRNP U protein binds to miRNA-30c and miRNA-24 in vitro. EMP derived from 
HCAEC cells transfected with si-hnRNP U negatively regulate HCAEC motility and 
positively promote proliferation. 
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